The sustained efficacy and safety data from the OLE study de-risk the TPIP program ahead of Phase 3 PALM-PAH topline results. Monitor enrollment updates and any interim data from the ongoing Phase 3 trials in PAH, PH-ILD, PPF, and IPF. The positive OLE data may increase probability of regulatory success and support a premium valuation for INSM.
INSM drugs
INSM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 16 $107.46entry
- T+1 · 4mo ago +0.80%α +1.79% · $108.32
- T+5 · 4mo ago −0.05%α +1.62% · $107.41
- T+20 · 3mo ago +17.56%α +13.94% · $126.33
- T+60 · 6w ago −6.38%α −10.09% · $100.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Insmed reported positive 12-month data from the ongoing open-label extension (OLE) study of TPIP (treprostinil palmitil inhalation powder) in pulmonary arterial hypertension (PAH). The data showed sustained improvements in exercise capacity (6MWD +55.7m for continued TPIP, +54.1m for placebo-crossed), NT-proBNP reduction (~60%), WHO Functional Class, and REVEAL Lite 2.0 mortality risk score, with no new safety signals. These results support the ongoing Phase 3 PALM-PAH trial and strengthen TPIP's profile as a potential best-in-class once-daily inhaled prostanoid.
Key Facts
- 12-month OLE data: mean 6MWD improvement of +55.7 meters (TPIP Continued) and +54.1 meters (Placebo Crossed) from baseline
- NT-proBNP reduced ~60% in both groups (geometric mean ratio 0.40 and 0.41)
- ~80% of patients achieved WHO Functional Class I or II; >25% achieved Class I
- Mean REVEAL Lite 2.0 score improved 2.0 points (Continued) and 1.4 points (Crossed); ~65% of all patients achieved Refined Low Risk status
- 91% patient completion rate at Month 12; no new safety signals; 4 deaths none considered drug-related
- TPIP is an investigational once-daily inhaled prostanoid; Phase 3 PALM-PAH trial is actively enrolling
Financial Impact
No financial data reported; clinical catalyst de-risks TPIP program and supports Phase 3 advancement
Risk Factors
- OLE study is open-label, single-arm, and non-placebo-controlled; results may not replicate in the Phase 3 randomized trial
- TPIP is investigational and not yet approved; regulatory approval is uncertain
- Competition from approved therapies (Tyvaso, Winrevair) and other pipeline candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-028602 |
| Document: ef20078093_ex99-1.htm | 0001140361-26-028602 |
| Document: ef20078093_8k.htm | 0001140361-26-028602 |
| Document: 0001140361-26-028602-index-headers.html | 0001140361-26-028602 |
| Document: 0001140361-26-028602-index.html | 0001140361-26-028602 |
| Document: 0001140361-26-028602.txt | 0001140361-26-028602 |
Track record
24 reports on INSM
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +31.86% at T+60 after the Mar 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $110.00 Now $122.88 +11.71% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $111.59 Now $122.88 +10.12% settles Nov 27
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $94.04 Now $122.88 +30.67% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $95.67 Now $122.88 +28.44% settles Nov 17
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $103.83 to $112.58 Now $122.88 +18.35% ▲ +8.43% +10.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 4/10 Entry $125.08 to $120.00 Now $122.88 −1.76% ▼ −4.06% −4.19% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $126.33 to $129.41 Now $122.88 −2.73% ▲ +2.44% +4.19% vs SPY
- Aug 6, 202614w ago 8-K Bullish 8/10 Entry $132.55 to $126.68 Now $122.88 −7.30% ▼ −4.43% −5.03% vs SPY
- Jul 24, 202616w ago Institutional Cluster Neutral 4/10 Entry $106.92 to $125.77 Now $122.88 +14.93% ▲ +17.63% +14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers